Snipr Biome
SNIPR Biome is a clinical-stage company developing CRISPR-based therapeutics to precisely target and eliminate specific bacteria in the human microbiome.
About
SNIPR Biome is a biotechnology company focused on developing a new class of precision antimicrobial drugs based on CRISPR technology. Their platform allows for the targeted removal of specific bacterial strains, addressing issues like antibiotic resistance, gut microbiome dysbiosis, and infectious diseases, while preserving beneficial bacteria.
Key facts
At-a-glance profile data
- Website
- sniprbiome.com
- Headquarters
- Copenhagen, Denmark
- Total funding
- $87M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 15 May 2024 | Series B | $37M | LSP Dementia Fund (managed by EQT Life Sciences) |
| 20 May 2020 | Undisclosed round | $50M | Lundbeckfonden Emerge, LSP, Novo Holdings |
Tech stack
Detected on sniprbiome.com, last scanned 4 Sept 2026. Run your own scan
- Frontend
- jQuery
- CMS / Builders
- Squarespace
- Email provider
- Microsoft 365
“SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy (June 1, 2023).”
View on Reddit“SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy.”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.
Frequently asked
How much funding has Snipr Biome raised?
Snipr Biome has raised a total of $87M in funding. The most recent round on record is Series B.